sickle cell disease therapeutics (Syros Pharmaceuticals)

N/A

Report date: 2025/03/20 09:48:14
NME

Base Information

Drug Namesickle cell disease therapeutics (Syros Pharmaceuticals)
Drug Alias NameLRF & NuRD modulators (Syros Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHemoglobin beta chain modulators
TargetsHemoglobin beta chain
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSyros Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSyros Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAnemia, Sickle Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A